Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.

Neil S, Huh J, Baronas V, Li X, McFarland HF, Cherukuri M, Mitchell JB, Quandt JA.

Brain Behav Immun. 2017 May;62:332-343. doi: 10.1016/j.bbi.2017.02.018. Epub 2017 Feb 24.

2.

Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination.

Yuen TJ, Johnson KR, Miron VE, Zhao C, Quandt J, Harrisingh MC, Swire M, Williams A, McFarland HF, Franklin RJ, Ffrench-Constant C.

Brain. 2013 Apr;136(Pt 4):1035-47. doi: 10.1093/brain/awt024. Epub 2013 Mar 21.

3.

Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis.

Quandt JA, Huh J, Baig M, Yao K, Ito N, Bryant M, Kawamura K, Pinilla C, McFarland HF, Martin R, Ito K.

J Immunol. 2012 Sep 15;189(6):2897-908. doi: 10.4049/jimmunol.1103087. Epub 2012 Aug 10.

4.

T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis.

Bagnato F, Salman Z, Kane R, Auh S, Cantor FK, Ehrmantraut M, Gallo A, Ikonomidou VN, Ohayon J, Pellicano C, Stern SK, McFarland HF.

Mult Scler. 2010 Oct;16(10):1203-12. doi: 10.1177/1352458510377223. Epub 2010 Aug 10.

PMID:
20699284
5.

Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis.

Bomboi G, Ikonomidou VN, Pellegrini S, Stern SK, Gallo A, Auh S, Evangelou IE, Agarwal J, Pellicano C, Ohayon JM, Cantor FK, Ehrmantraut M, McFarland HF, Kane RL, Bagnato F.

J Neuroimaging. 2011 Apr;21(2):e57-63. doi: 10.1111/j.1552-6569.2010.00488.x.

PMID:
20626570
6.

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS.

Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4.

PMID:
20610349
7.

Relationship of cortical atrophy to fatigue in patients with multiple sclerosis.

Pellicano C, Gallo A, Li X, Ikonomidou VN, Evangelou IE, Ohayon JM, Stern SK, Ehrmantraut M, Cantor F, McFarland HF, Bagnato F.

Arch Neurol. 2010 Apr;67(4):447-53. doi: 10.1001/archneurol.2010.48.

PMID:
20385911
8.

Ring and nodular multiple sclerosis lesions: a retrospective natural history study.

Davis M, Auh S, Riva M, Richert ND, Frank JA, McFarland HF, Bagnato F.

Neurology. 2010 Mar 9;74(10):851-6. doi: 10.1212/WNL.0b013e3181d31df5.

9.

Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.

McFarland HF.

Ann Indian Acad Neurol. 2009 Oct;12(4):254-63. doi: 10.4103/0972-2327.58284.

10.

Examination of the role of MRI in multiple sclerosis: a problem orientated approach.

McFarland HF.

Results Probl Cell Differ. 2010;51:287-301. doi: 10.1007/400_2009_33. Review.

PMID:
19960380
11.

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Bielekova B, Richert N, Howard T, Packer AN, Blevins G, Ohayon J, McFarland HF, Stürzebecher CS, Martin R.

Mult Scler. 2009 Oct;15(10):1206-14. doi: 10.1177/1352458509345903. Epub 2009 Sep 23.

12.

Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T.

Tovar-Moll F, Evangelou IE, Chiu AW, Richert ND, Ostuni JL, Ohayon JM, Auh S, Ehrmantraut M, Talagala SL, McFarland HF, Bagnato F.

AJNR Am J Neuroradiol. 2009 Aug;30(7):1380-6. doi: 10.3174/ajnr.A1564. Epub 2009 Apr 15.

13.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

14.

Alemtuzumab versus interferon beta-1a: implications for pathology and trial design.

McFarland HF.

Lancet Neurol. 2009 Jan;8(1):26-8. doi: 10.1016/S1474-4422(08)70280-1. No abstract available.

PMID:
19081510
15.

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.

Chiu AW, Richert N, Ehrmantraut M, Ohayon J, Gupta S, Bomboi G, Gaindh D, Cantor FK, Frank JA, McFarland HF, Bagnato F.

Arch Neurol. 2009 Jan;66(1):39-43. doi: 10.1001/archneur.66.1.noc80047. Epub 2008 Nov 10.

PMID:
19001157
16.

Different development of myelin basic protein agonist- and antagonist-specific human TCR transgenic T cells in the thymus and periphery.

Kawamura K, Yao K, Shukaliak-Quandt JA, Huh J, Baig M, Quigley L, Ito N, Necker A, McFarland HF, Muraro PA, Martin R, Ito K.

J Immunol. 2008 Oct 15;181(8):5462-72.

17.

Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH.

Mult Scler. 2008 Nov;14(9):1157-74. doi: 10.1177/1352458508096878. Epub 2008 Sep 19.

18.

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses.

Petkau J, Reingold SC, Held U, Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF, Wolinsky JS.

Mult Scler. 2008 Jul;14(6):770-8. doi: 10.1177/1352458507088104. Epub 2008 Jun 5.

19.

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS.

Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d.

PMID:
18362273
20.

The B cell--old player, new position on the team.

McFarland HF.

N Engl J Med. 2008 Feb 14;358(7):664-5. doi: 10.1056/NEJMp0708143. No abstract available.

PMID:
18272890
21.

Multiple sclerosis: a complicated picture of autoimmunity.

McFarland HF, Martin R.

Nat Immunol. 2007 Sep;8(9):913-9. Review.

PMID:
17712344
22.

A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.

Chiu AW, Ehrmantraut M, Richert ND, Ikonomidou VN, Pellegrini S, McFarland HF, Frank JA, Bagnato F.

Clin Exp Immunol. 2007 Oct;150(1):61-7. Epub 2007 Jul 30.

23.

In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis.

Bagnato F, Butman JA, Gupta S, Calabrese M, Pezawas L, Ohayon JM, Tovar-Moll F, Riva M, Cao MM, Talagala SL, McFarland HF.

AJNR Am J Neuroradiol. 2006 Nov-Dec;27(10):2161-7.

24.

Natalizumab and immune cells.

McFarland HF, Jacobson S.

Arch Neurol. 2006 Oct;63(10):1366-7. No abstract available.

PMID:
17030649
25.

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis.

Richert ND, Howard T, Frank JA, Stone R, Ostuni J, Ohayon J, Bash C, McFarland HF.

Neurology. 2006 Feb 28;66(4):551-6.

PMID:
16505310
26.

Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis.

Bagnato F, Butman JA, Mora CA, Gupta S, Yamano Y, Tasciyan TA, Solomon JM, Santos WJ, Stone RD, McFarland HF, Jacobson S.

J Neurovirol. 2005 Dec;11(6):525-34.

PMID:
16338746
27.
28.

Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.

Gupta S, Solomon JM, Tasciyan TA, Cao MM, Stone RD, Ostuni JL, Ohayon JM, Muraro PA, Frank JA, Richert ND, McFarland HF, Bagnato F.

Mult Scler. 2005 Dec;11(6):658-68.

PMID:
16320725
29.

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS.

Ann Neurol. 2005 Dec;58(6):840-6. Review.

PMID:
16283615
30.

MRI as a marker for disease heterogeneity in multiple sclerosis.

Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF.

Neurology. 2005 Oct 11;65(7):1071-6.

PMID:
16217061
31.

Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.

Bagnato F, Gupta S, Richert ND, Stone RD, Ohayon JM, Frank JA, McFarland HF.

Arch Neurol. 2005 Nov;62(11):1684-8. Epub 2005 Sep 12.

PMID:
16157739
32.

Initiation of dialysis in a patient with diabetes and chronic kidney disease.

McFarland HF.

Nephrol Nurs J. 2005 Mar-Apr;32(2):219-20. No abstract available.

PMID:
15889806
33.

Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis.

Morgen K, Crawford AL, Stone RD, Martin R, Richert ND, Frank JA, McFarland HF.

Mult Scler. 2005 Apr;11(2):146-8.

PMID:
15794386
34.

Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients.

Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, Campbell C, Memon S, Nagle JW, Hakim FT, Gress RE, McFarland HF, Burt RK, Martin R.

J Exp Med. 2005 Mar 7;201(5):805-16. Epub 2005 Feb 28.

35.

Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging.

Morgen K, McFarland HF, Pillemer SR.

Semin Arthritis Rheum. 2004 Dec;34(3):623-30. Review.

PMID:
15609267
36.

Re: GAMES issue.

McFarland HF, Martin R.

J Neuroimmunol. 2004 Aug;153(1-2):3. No abstract available.

PMID:
15334745
37.

Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice.

Quandt JA, Baig M, Yao K, Kawamura K, Huh J, Ludwin SK, Bian HJ, Bryant M, Quigley L, Nagy ZA, McFarland HF, Muraro PA, Martin R, Ito K.

J Exp Med. 2004 Jul 19;200(2):223-34.

38.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8. Epub 2004 May 25. Erratum in: Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17565.

39.

Limited repertoire of HLA-DRB1*0401-restricted MBP111-129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential.

Huh J, Yao K, Quigley L, Ludwin SK, McFarland HF, Muraro PA, Martin R, Ito K.

J Neuroimmunol. 2004 Jun;151(1-2):94-102.

PMID:
15145608
40.

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF.

Neurology. 2004 Mar 9;62(5):719-25.

PMID:
15007120
41.

Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease.

Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM.

Hum Mol Genet. 2003 Sep 1;12(17):2191-9. Epub 2003 Jul 8.

PMID:
12915464
42.

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

Bagnato F, Jeffries N, Richert ND, Stone RD, Ohayon JM, McFarland HF, Frank JA.

Brain. 2003 Aug;126(Pt 8):1782-9. Epub 2003 Jun 23.

PMID:
12821527
43.

Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b.

Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA, McFarland HF.

Neurology. 2003 Jun 10;60(11):1849-51.

PMID:
12796549
44.

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF.

Brain. 2003 Jun;126(Pt 6):1419-29.

PMID:
12764062
45.

Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders.

Muraro PA, Wandinger KP, Bielekova B, Gran B, Marques A, Utz U, McFarland HF, Jacobson S, Martin R.

Brain. 2003 Jan;126(Pt 1):20-31.

46.

Impaired renal function in progressive multiple sclerosis.

Calabresi PA, Austin H, Racke MK, Goodman A, Choyke P, Maloni H, McFarland HF.

Neurology. 2002 Dec 10;59(11):1799-801.

PMID:
12473777
47.

T cell response to 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase) in multiple sclerosis patients.

Muraro PA, Kalbus M, Afshar G, McFarland HF, Martin R.

J Neuroimmunol. 2002 Sep;130(1-2):233-42.

PMID:
12225906
48.

Lytic therapy in central venous catheters for hemodialysis.

McFarland HF, Dinwiddie L, Ferrell J, Forloines-Lynn S.

Nephrol Nurs J. 2002 Aug;29(4):355-60; quiz 361-2. Review.

PMID:
12224368
49.

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.

Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA.

Neurology. 2002 Sep 10;59(5):688-94.

PMID:
12221158
50.

Surviving a 500-year flood.

McFarland HF.

Nephrol Nurs J. 2001 Oct;28(5):504-6, 509-10.

PMID:
12143426

Supplemental Content

Loading ...
Support Center